1、乳腺癌辅助内分泌治乳腺癌辅助内分泌治疗相关试验疗相关试验2021/4/272乙烯雌酚MPAMATAMAGZoladex雌激素雌激素孕激素孕激素抗雌激素抗雌激素芳香化酶抑制芳香化酶抑制(失活失活)剂剂肾上腺皮质激肾上腺皮质激素类素类Droloxifene兰他隆ExemestaneToremifeneArimidexFemara(Letrozole)2021/4/2732021/4/2742021/4/275TrialsFE2021/4/276TrialsFE2021/4/277TrialsFE2021/4/278TrialsFE2021/4/279TrialsFEAdrenal glandPer
2、ipheral tissuesPostmenopausal womenTumor=Estrogen=AndrostenedioneReceptor2021/4/2710EstroneEstradiolTestosteroneAndrostenedioneCholesterolCortisolProgesteroneAldosteronePregnenolone2021/4/2711FirstSecondThirdAminoglutethimideFadrozoleAnastrozoleLetrozoleTestolactoneFormestaneExemestane2021/4/2712202
3、1/4/27132021/4/2714P=0.032021/4/2715P=0.0314个月21个月2021/4/27162021/4/2717AdexProdFEMedian time to death(months)2 year survival rate(%)P 0.052021/4/27182021/4/2719458Letrozole458Tamoxifen Progression Cross-OverProgressionSurvival Follow-upLetrozoleTamoxifen2021/4/2720P0.001P0.0012021/4/2721 Letrozole
4、Tamoxifen 0.00.10.20.30.40.50.60.70.80.91.00 3 6 91215182124MonthsProportion of patients without progression2021/4/27222021/4/2723Double-blind,double-dummy,randomized,parallel group,multicenter(55 centers in 16 countries),phase IIb/III trialFemara(letrozole)2.5 mg o.d.Tamoxifen20 mg o.d.SurgeryFollo
5、w-up therapy(investigator driven)4 monthsProtocol 024-Data on file,Novartis Pharma AG2021/4/2724(2002年年)(2004年年)(2003年年)ATAC 试验试验 IES 031试验试验 MA-17试验试验 阿那曲唑阿那曲唑 依西美坦依西美坦 来曲唑来曲唑辅助辅助化疗化疗5 年辅助三苯氧胺是标准手段年辅助三苯氧胺是标准手段 （2005年）年）（2005年年)BIG 1-98试验试验 ARNO试验试验 来曲唑来曲唑 阿那曲唑阿那曲唑2021/4/27252021/4/27262021/4/27272021/4/27282021/4/27292021/4/27302021/4/27312021/4/27322021/4/2733
